The New Zealand Obese Mouse: Polygenic model of obesity, glucose intolerance, and the metabolic syndrome

Animal Models of Diabetes, Second Edition: Frontiers in Research

Volumn , Issue , 2007, Pages 139-158

  Fam, Barbara C ^a   Andrikopoulos, Sofianos ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 66849097310     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (72)

1. Andrikopoulos S, Proietto J. (1995) The biochemical basis of increased hepatic glucose production in a mouse model of type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 38:1389-1396.
2. Andrikopoulos S, Rosella G, Gaskin E, et al. (1993) Impaired regulation of hepatic fructose- 1,6-bisphosphatase in the New Zealand obese mouse model of NIDDM. Diabetes 42:1731-1736.
3. Andrikopoulos S, Rosella G, Kaczmarczyk SJ, et al. (1996) Impaired regulation of hepatic fructose-1,6-bisphosphatase in the New Zealand obese mouse: An acquired defect. Metabolism 45:622-626.
4. Andrikopoulos S, Thorburn A, Proietto J. (2001) The New Zealand obese mouse: a polygenic model of Type 2 diabetes. In Animal Models of Diabetes: A Primer, ed. A Sima, E Shafrir, Harwood Academic, Amsterdam, 171-184.
5. Aston-Mourney K, Proietto J, Andrikopoulos S. (2005) Investigational agents that protect pancreatic islet beta-cells from failure. Expert Opin Invest Drugs 14:1241-1250.
6. Becker W, Kluge R, Kantner T, et al. (2004) Differential hepatic gene expression in a polygenic mouse model with insulin resistance and hyperglycemia: Evidence for a combined transcriptional dysregulation of gluconeogenesis and fatty acid synthesis. J Mol Endocrinol 32:195-208.
7. Bielschowsky M, Bielschowsky F. (1953) A new strain of mice with hereditary obesity. Proc Univ Otago Med School 31:29-31.
8. Bielschowsky M, Bielchowsky F. (1956) The New Zealand strain of obese mice. Their response to stilboestrol and to insulin. Austral J Exp Biol 34:181-1898.
9. Cameron DP, Opat F, Insch S. (1974) Studies of immunoreactive insulin secretion in NZO mice in vivo. Diabetologia 10:649-654.
10. Crofford OB, Davis CKJ. (1965) Growth characteristics, glucose tolerance and insulin sensitivity of New Zealand obese mice. Metabolism 14:271-280.
11. Davis TR, Mayer J. (1954) Imperfect homeothermia in the hereditary obese-hyperglycemic syndrome of mice. Am J Physiol 177:222-226.
12. Ferreras L, Kelada ASMK, McCoy M, Proietto J. (1994) Early decrease in GLUT4 protein levels in brown adipose tissue of New Zealand obese mice. Int J Obesity 18:760-765.
13. Giesen K, Plum L, Kluge R, et al. (2003) Diet-dependent obesity and hypercholesterolemia in the New Zealand obese mouse: Identification of a quantitative trait locus for elevated serum cholesterol on the distal mouse chromosome 5. Biochem Biophys Res Commun 304:812-817.
14. Groop LC, Kankuri M, Schalin-Janti C, et al. (1993) Association between polymorphism of the glycogen synthase gene and non-insulin-dependent diabetes mellitus. N Engl J Med 328:10-14.
15. Halaas JL, Boozer C, Blair-West J, et al. (1997) Physiological response to long-term peripheral and central leptin infusion in lean and obese mice. Proc Natl Acad Sci USA 94:8878-8883.
16. Harrison LC, Itin A.(1979) A possible mechanism for insulin resistance and hyperglycemia in NZO mice. Nature 279:334-336.
17. Herberg L, Major E, Hennigs U, et al. (1970) Differences in the development of the obesehyperglycemic syndrome in ob/ob and NZO mice. Diabetologia 6:292-299.
18. Igel M, Becker W, Herberg L, Joost HG. (1997) Hyperleptinemia, leptin resistance, and polymorphic leptin receptor in the New Zealand obese mouse. Endocrinology 138:4234-4239.
19. Jurgens HS, Schurmann A, Kluge R, et al. (2006) Hyperphagia, lower body temperature, and reduced running wheel activity precede development of morbid obesity in New Zealand obese mice. Physiol Genomics 25:234-241.
20. Kluge R, Giesen K, Bahrenberg G, et al. (2000) Quantitative trait loci for obesity and insulin resistance (Nob1, Nob2) and their interaction with the leptin receptor allele (LeprA720T/T1044I) in New Zealand obese mice. Diabetologia 43:1565-1572.
21. Koza RA, Flurkey K, Graunke DM, et al. (2004) Contributions of dysregulated energy metabolism to type 2 diabetes development in NZO/H1Lt mice with polygenic obesity. Metabolism 53:799-808.
22. Lamont BJ, Visinoni S, Fam BC, et al. (2006) Expression of human fructose-1,6-bisphosphatase in the liver of transgenic mice results in increased glycerol gluconeogenesis. Endocrinology 147:2764-2772.
23. Lander ES, Botstein D. (1989) Mapping Mendelian factors underlying quantitative traits using RFLP linkage maps. Genetics 121:185-199.
24. Larkins RG. (1971) Plasma growth hormone in the New Zealand obese mouse. Diabetologia 7:302-307.
25. Larkins RG. (1972) Endocrine abnormalities in the NZO mouse (PhD thesis). Department of Medicine, Royal Melbourne Hospital, University of Melbourne, Melbourne.
26. Larkins RG. (1973a) Defective insulin secretion in the NZO mouse: In vitro studies. Endocrinology 93:1052-1056.
27. Larkins RG. (1973b) Defective insulin secretory response to glucose in the New Zealand obese mouse. Improvement with restricted diet. Diabetes 22:251-255.
28. Larkins RG, Martin FIR. (1972) Selective defect in insulin release in one form of spontaneous laboratory diabetes. Nature 235:86-88.
29. Larkins RG, Simeonova L, Veroni MC. (1980) Glucose utilization in relation to insulin secretion in NZO and C57Bl mouse islets. Endocrinology 107:1634-1638.
30. Leiter EH, Reifsnyder PC. (2004) Differential levels of diabetogenic stress in two new mouse models of obesity and type 2 diabetes. Diabetes 53:S4-11.
31. Leiter EH, Reifsnuder PC, Flurkey K, et al. (1998) NIDDM genes in mice. Deleterious synergism by both parental genomes contributes to diabetogenic thresholds. Diabetes 47:1287-1295.
32. Leiter EH, Reifsnyder PC, Zhang W, et al. (2006) Differential endocrine responses to rosiglitazone therapy in new mouse models of type 2 diabetes. Endocrinology 147:919-926.
33. Lovell-Smith CJ, Sneyd JGT. (1973) Lipolysis and adenosine 3',5'-cyclic monophosphate in adipose tissue of the New Zealand obese mouse. J Endocrinol 56:1-11.
34. Lovell-Smith CJ, Sneyd JGT. (1974) Lipolysis and adenosine 3',5'-cyclic monophosphate in adipose tissue of the New Zealand obese mouse; the activities of adipose tissue adenyl cyclase and phosphodiesterase. Diabetologia, 10:655-659.
35. Macaulay SL, Larkins RG. (1988) Impaired insulin action in adipocytes of New Zealand obese mice: A role for postbinding defects in pyruvate dehydrogenase and insulin mediator activity. Metabolism 37:958-965.
36. McInerney MF, Najjar SM, Brickley D, et al. (2004) Anti-insulin receptor autoantibodies are not required for type 2 diabetes pathogenesis in NZL/Lt mice, a New Zealand obese (NZO)-derived mouse strain. Exp Diabesity Res 5:177-185.
37. Melez KA, Harrison LC, Gilliam JN, Steinberg AD. (1980) Diabetes is associated with autoimmunity in the New Zealand obese (NZO) mouse. Diabetes 29:835-840.
38. Nurjhan N, Consoli A, Gerich J. (1992) Increased lipolysis and its consequence on gluconeogenesis in non-insulin-dependent diabetes mellitus. J Clin Invest 89:169-175.
39. Ortlepp JR, Kluge R, Giesen K, et al. (2000) A metabolic syndrome of hypertension, hyperinsulinaemia and hypercholesterolaemia in the New Zealand obese mouse. Eur J Clin Invest 30:195-202.
40. Pan HJ, Reifsnyder P, Vance DE, et al. (2005) Pharmacogenetic analysis of rosiglitazone-induced hepatosteatosis in new mouse models of type 2 diabetes. Diabetes 54:1854-62.
41. Plum L, Giesen K, Kluge R, et al. (2002) Characterization of the mouse diabetes susceptibilty locus Nidd/SJL: Islet cell destruction, interaction with the obesity QTL Nob1, and effect of dietary fat. Diabetologia 45:823-30.
42. Plum L, Kluge R, Giesen K, et al. (2000) Type 2 diabetes-like hyperglycemia in a backcross model of NZO and SJL mice: Characterization of a susceptibility locus on chromosome and its relation with obesity. Diabetes 49:1590-1596.
43. Proietto J, Larkins RG. (1993) A perspective on the New Zealand obese mouse. In Lessons from Animal Diabetes, ed. Shafrir, E. Smith- Gordon, London, 4:65-74.
44. Proks P, Reimann F, Green N, et al. (2002) Sulfonylurea stimulation of insulin secretion. Diabetes 51:S368-376.
45. Puhakainen I, Koivisto VA, Uki-Jarvinen H. (1992) Lipolysis and gluconeogenesis from glycerol are increased in patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 75:789-794.
46. Reifsnyder PC, Churchill G, Leiter EH. (2000) Maternal environment and genotype interact to establish diabesity in mice. Genome Res 10:1568-1578.
47. Reifsnyder PC, Leiter EH. (2002) Deconstructing and reconstructing obesity-induced diabetes (diabesity) in mice. Diabetes 51:825-832.
48. Rizk NM, Liu LS, Eckel J. (1998) Hypothalamic expression of neuropeptide-Y in the New Zealand obese mouse. Int J Obesity 22:1172-1177.
49. Rongstad, R. (1979) Rate-limiting steps in metabolic pathways. J Biol Chem 254:1875-1878.
50. Rosella G, Zajac JD, Baker L, et al. (1995) Impaired glucose tolerance and increased weight gain in transgenic rats overexpressing a non-insulin-responsive phosphoenolpyruvate carboxykinase gene. Mol Endocrinol 9:1396-1404.
51. Rudorff KH, Huchzermeyer H, Windeck R, Staib W. (1970) Uber den Einfluss von insulin auf die Alaningluconeogenese in der isoliert perfundierten Leberber von New Zealand obese mice. Eur J Biochem 16:481-486.
52. Seino S, Iwanaga T, Nagashima K, Miki T. (2000) Diverse roles of K(ATP) channels learned from Kir6.2 genetically engineered mice. Diabetes 49:311-318.
53. Serreze DV, Prochazka M, Reifsnyder PC, et al. (1994) Use of recombinant congenic and congenic strains of NOD mice to identify a new insulin-dependent diabetes resistance gene. J Exp Med 180:1553-1558.
54. Song S, Andrikopoulos S, Filippis C, et al. (2001) Mechanism of fat-induced hepatic gluconeogenesis: Effect of metformin. Am J Physiol 281:E275-E282.
55. Spiegelman BM. (1998) PPAR-gamma: Adipogenic regulator and thiazolidinedione receptor. Diabetes 47:507-514.
56. Stauffacher W, Renold AE. (1969) Effect of insulin in vivo on diaphragm and adipose tissue of obese mice. Am J Physiol 216:98-105.
57. Taylor BA, Wnek C, Schroeder D, Phillips SJ. (2001) Multiple obesity QTLs identified in an intercross between the NZO (New Zealand obese) and the SM (small) mouse strains. Mamm Genome 12:95-103.
58. Thorburn A, Litchfield A, Fabris S, Proietto J. (1995) Abnormal transient rise in hepatic glucose production after oral glucose in non-insulin-dependent diabetic subjects. Diabetes Res Clin Prac 28:127-135.
59. Thorburn AW, Holdsworth A, Proietto J, Morahan G. (2000) Differential and genetically separable associations of leptin with obesity-related traits. Int J Obesity 24:742-750.
60. Tiikkainen M, Hakkinen AM, Korsheninnikova E, et al. (2004) Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 53:2169-2176.
61. Upton JD. (1984) Intravenous glucose tolerance tests in the New Zealand strains of mice. Horm Metab Res 16:290-292.
62. Upton JD, Sneyd JGT, Livesey J. (1980) Blood glucose, plasma insulin and plasma glucagon in NZO mice. Horm Metab Res 12:173-174.
63. Upton JD, Sneyd JGT, Rennie PIC. (1979) Insulin resistance in the New Zealand obese mouse (NZO): Lipolysis and lipogenesis in isolated adipocytes. Arch Biochem Biophys 197:139-148.
64. Valera A, Pujol A, Pelegrin M, Bosch F. (1994) Transgenic mice overexpressing phosphoenolpyruvate carboxykinase develop non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci USA 91:9151-9154.
65. van Wezel T, Ruivenkamp CA, Stassen AP, et al. (1999) Four new colon cancer susceptibility loci, Scc6 to Scc9 in the mouse. Cancer Res 59:4216-4218.
66. Veroni MC, Larkins RG. (1986) Evolution of insulin resistance in isolated soleus muscle of the NZO mouse. Horm Metab Res 18:299-302.
67. Veroni MC, Proietto J, Larkins, RG. (1991) Evolution of insulin resistance in New Zealand obese mice. Diabetes 40:1480-1487.
68. Watkins SM, Reifsnyder PR, Pan HJ, et al. (2002) Lipid metabolome-wide effects of the PPARgamma agonist rosiglitazone. J Lipid Res 43:1809-1817.
69. Willms B, Ben-Ami P, Söling HD. (1970) Hepatic enzyme activities of glycolysis and gluconeogenesis in diabetes of man and laboratory animals. Horm Metab Res 2:135-141.
70. Yki-Jarvinen H. (1990) Acute and chronic effects of hyperglycaemia on glucose metabolism. Diabetologia 33:579-585.
71. Zimmet P, Boyko EJ, Collier GR, de Courten M. (1999) Etiology of the metabolic syndrome: Potential role of insulin resistance, leptin resistance, and other players. Ann NY Acad Sci 892:25-44.
72. Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J. (2005) The metabolic syndrome: A global public health problem and a new definition. J Atheroscler Thromb 12:295-300.